Traditionally, TNBC diagnosis is dictated by immunohistochemistry (IHC) (to assess ER, PgR, and HER2 status), although in clinical practice, it is often a two-step process, combining morphological imaging and IHC to identify specific cancer biomarkers, which can help predict potential treatment outcomes or provide the best clinically available targeted therapy (Wang et al. 2008; Gao et al. 2014; Wang et al. 2021; Sanchez et al. 2021). This evidence concerns the gene ESR1 and cancer.